|
🐜
|
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
23 auth.
Mellen Center,
J. A. Cohen,
Md,
Canada,
L. Arnold,
E. Fox,
Jeff Rey,
A. Cohen,
A. Coles,
Douglas L Arnold,
...
C. Confavreux,
E. Fox,
H. Hartung,
E. Havrdová,
Krzysztof W Selmaj,
Howard L. Weiner,
E. Fisher,
Vesna V. Brinar,
G. Giovannoni,
M. Stojanovic,
Bella I Ertik,
S. Lake,
D. Margolin
|
10 |
2012 |
10
🐜
|
